Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Feb 25:9:797811.
doi: 10.3389/fsurg.2022.797811. eCollection 2022.

The Correlation Between Intra-Abdominal Pressure and Tolerance to Postoperative Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei

Junye Yu  1 , Lifei Yu  2 , Lin Su  3 , Ying Shi  4
Affiliations

The Correlation Between Intra-Abdominal Pressure and Tolerance to Postoperative Hyperthermic Intraperitoneal Chemotherapy for Pseudomyxoma Peritonei

Junye Yu et al. Front Surg. .

Abstract

Objective: To evaluate the correlation between pain intensity and comfort level in patients with pseudomyxoma peritoneum (PMP) before and after hyperthermic intraperitoneal chemotherapy (HIPEC).

Methods: From June 2018 to June 2019, patients who underwent HIPEC for PMP after surgical treatment in our institute were selected. The intra-abdominal pressure (IAP) and pain intensity (PI) before and after HIPEC were recorded, and the correlation between them was analyzed.

Results: Seventy-four patients received HIPEC 253 times. IAP and PI were significantly higher after perfusion than before perfusion (P < 0.05). When IAP < 12 cmH2O, the change of PI was not correlated to the increase of IAP, and the patient tolerated the treatment. However, when IAP > 12 cmH2O, the increase of PI was significantly associated with IAP and cause significant discomfort during the treatment.

Conclusion: IAP may be a monitoring index for the comfort of PMP patients during the postoperative HIPEC treatment.

Keywords: comfort assessment; intra-abdominal pressure; postoperative hyperthermic intraperitoneal chemotherapy; pseudomyxoma peritonei; surgical oncology.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
IAPs measured by transabdominal and transvesical method before (A) and after (B) perfusion.
Figure 2
Figure 2
Pressure distribution in the abdominal cavity before and after perfusion.
Figure 3
Figure 3
Distribution of pain score before and after perfusion.
Figure 4
Figure 4
Forest diagram of the relationship between IAP and PI after perfusion.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Smeenk RM, van Velthuysen ML, Verwaal VJ, Zoetmulder FA. Appendiceal neoplasms and pseudomyxoma peritonei: a population based study. Eur J Surg Oncol. (2008) 34:196–201. 10.1016/j.ejso.2007.04.002 - DOI - PubMed
    1. Gough DB, Donohue JH, Schutt AJ, Gonchoroff N, Goellner JR, Wilson TO, et al. . Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg. (1994) 219:112–9. 10.1097/00000658-199402000-00002 - DOI - PMC - PubMed
    1. Miner TJ, Shia J, Jaques DP, Klimstra DS, Brennan MF, Coit DG. Long-term survival following treatment of pseudomyxoma peritonei: an analysis of surgical therapy. Ann Surg. (2005) 241:300–8. 10.1097/01.sla.0000152015.76731.1f - DOI - PMC - PubMed
    1. Delhorme JB, Villeneuve L, Bouché O, Averous G, Dohan A, Gornet JM, et al. . Appendiceal tumors and pseudomyxoma peritonei: French Intergroup Clinical Practice Guidelines for diagnosis, treatments and follow-up (RENAPE, RENAPATH, SNFGE, FFCD, GERCOR, UNICANCER, SFCD, SFED, SFRO, ACHBT, SFR). Dig Liver Dis. (2022) 54:30–9. 10.1016/j.dld.2021.10.005 - DOI - PubMed
    1. Mercier F, Dagbert F, Pocard M, Goéré D, Quenet F, Wernert R, et al. . Recurrence of pseudomyxoma peritonei after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. BJS Open. (2019) 3:195–202. 10.1002/bjs5.97 - DOI - PMC - PubMed